January 11, 2022 -- Twist Bioscience has developed an innovative, low-cost, scarless, and scalable enzymatic DNA synthesis process. With these comprehensive capabilities in synthesis, Twist offers multiple approaches to serve the growing number of markets leveraging synthetic DNA, the company said.
Scientists at Twist have worked for the past 18 months to develop a novel approach to synthesize strands of DNA enzymatically. Twist has developed novel enzyme/nucleotide conjugates that drastically reduce the quantity of nucleotide triphosphate used by traditional enzymatic approaches, which significantly reduces the cost and offers a much more sustainable method of synthesis, Twist said.
In addition, the link between the enzyme and the nucleotide developed by Twist maintains the integrity of the DNA, with no "scars" on the nucleobase from linker molecules. This allows the resulting enzymatically created synthetic DNA strand to be used interchangeably with naturally occurring DNA.
Emily Leproust, PhD, CEO and co-founder of Twist unveiled the advancement during her presentation at the 40th Annual J.P. Morgan Healthcare Conference.
Twist also announced that it is enabling next-generation sequencing workflows for PacBio and Singular Genomics. Twist has customized its target enrichment and library preparation workflows for both sequencing platforms to allow customers to experience the uniformity of the Twist Bioscience solution, the company said.